Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Short-term Investments (2016 - 2025)

Historic Short-term Investments for Pharma (IGC) over the last 15 years, with Q3 2025 value amounting to $25000.0.

  • Pharma's Short-term Investments changed N/A to $25000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $25000.0, marking a year-over-year change of. This contributed to the annual value of $154000.0 for FY2023, which is N/A changed from last year.
  • Latest data reveals that Pharma reported Short-term Investments of $25000.0 as of Q3 2025.
  • In the past 5 years, Pharma's Short-term Investments ranged from a high of $227000.0 in Q2 2023 and a low of $25000.0 during Q3 2025
  • For the 4-year period, Pharma's Short-term Investments averaged around $123571.4, with its median value being $98000.0 (2023).
  • Its Short-term Investments has fluctuated over the past 5 years, first tumbled by 9842.55% in 2021, then tumbled by 4922.28% in 2023.
  • Pharma's Short-term Investments (Quarter) stood at $80000.0 in 2021, then increased by 10.0% to $88000.0 in 2022, then grew by 11.36% to $98000.0 in 2023, then plummeted by 74.49% to $25000.0 in 2025.
  • Its last three reported values are $25000.0 in Q3 2025, $98000.0 for Q3 2023, and $227000.0 during Q2 2023.